Kaisa Group Holdings Ltd on Wednesday said it planned to spend $322 million buying 19 percent of blood products firm Zhenxing Biopharmaceutical & Chemical Co Ltd, as the once-troubled Chinese property developer continues to diversify.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com